tiprankstipranks
Trending News
More News >
Antengene Corporation Limited (DE:722)
:722
Germany Market

Antengene Corporation Limited (722) Drug Pipeline

Compare
0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Lenalidomide, Rituximab, Atg-010
Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma
Phase I/II
Terminated
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
Feb 09, 2022
Svd (Selinexor+Bortezomib+Dexamethasone), Vd (Bortezomib+Dexamethasone)
Relapsed Or Refractory Multiple Myeloma
Phase III
Active Not Recruiting
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Jun 17, 2021
Tislelizumab, Ice [Ifosfamide+Carboplatin+Etoposide], Gemox [Gemcitabine+Oxaliplatin]
Peripheral T-Cell Lymphoma, Nk/T-Cell Lymphoma
Phase I/II
Active Not Recruiting
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
May 25, 2020
Atg-010 60 Mg, Orally, Twice Weekly, Each 4 Week (28-Day) A Cycle
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)
Phase II
Completed
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jun 18, 2019

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Antengene Corporation Limited (722) have in its pipeline
      722 is currently developing the following drugs: Lenalidomide, Rituximab, Atg-010, Svd (Selinexor+Bortezomib+Dexamethasone), Vd (Bortezomib+Dexamethasone), Tislelizumab, Ice [Ifosfamide+Carboplatin+Etoposide], Gemox [Gemcitabine+Oxaliplatin]. These drug candidates are in various stages of clinical development as the company works toward FDA approval.